- Home
- SILC vs CRBP Comparison
SILC vs CRBP Comparison
Compare SILC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- CRBP
- Stock Information
- Founded
- SILC 1987
- CRBP 2009
- Country
- SILC Israel
- CRBP United States
- Employees
- SILC N/A
- CRBP N/A
- Industry
- SILC Computer Manufacturing
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- CRBP Health Care
- Exchange
- SILC Nasdaq
- CRBP Nasdaq
- Market Cap
- SILC 91.4M
- CRBP 73.4M
- IPO Year
- SILC 1994
- CRBP N/A
- Fundamental
- Price
- SILC $14.68
- CRBP $5.03
- Analyst Decision
- SILC Hold
- CRBP Strong Buy
- Analyst Count
- SILC 2
- CRBP 10
- Target Price
- SILC N/A
- CRBP $60.89
- AVG Volume (30 Days)
- SILC 25.6K
- CRBP 211.7K
- Earning Date
- SILC 04-28-2025
- CRBP 03-11-2025
- Dividend Yield
- SILC N/A
- CRBP N/A
- EPS Growth
- SILC N/A
- CRBP N/A
- EPS
- SILC N/A
- CRBP N/A
- Revenue
- SILC $58,114,000.00
- CRBP N/A
- Revenue This Year
- SILC $6.22
- CRBP N/A
- Revenue Next Year
- SILC $19.10
- CRBP $270.01
- P/E Ratio
- SILC N/A
- CRBP N/A
- Revenue Growth
- SILC N/A
- CRBP N/A
- 52 Week Low
- SILC $11.35
- CRBP $4.92
- 52 Week High
- SILC $18.24
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- SILC 40.88
- CRBP 25.32
- Support Level
- SILC $14.38
- CRBP $5.76
- Resistance Level
- SILC $15.37
- CRBP $6.17
- Average True Range (ATR)
- SILC 0.73
- CRBP 0.40
- MACD
- SILC 0.04
- CRBP 0.01
- Stochastic Oscillator
- SILC 31.76
- CRBP 5.33
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.